Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1997 Mar 1;25(5):983–986. doi: 10.1093/nar/25.5.983

Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter.

A M Metcalfe 1, R M Dixon 1, G K Radda 1
PMCID: PMC146535  PMID: 9023107

Abstract

p53 transactivates the expression of a variety of genes by binding to specific DNA sequences within the promoter. We have investigated the ability of wild-type p53 and a non-DNA binding p53 mutant to activate the hepatocyte growth factor/scatter factor (HGF/SF) promoter using chloramphenicol acetyltransferase reporter constructs. We also used deletion sequences of the HGF/SF promoter to identify which regions, if any, were responsible for p53 binding. Our results show that wild-type but not mutant p53 activates the HGF/SF promoter when using -3000 and -755 bp upstream of the HGF/SF gene. This activation is lost when promoter sequences covering -365 and -239 bp are used. Analysis of the DNA sequence between -365 and -755 bp shows one putative p53 half-site with 80% homology to the consensus sequence and another half-site 3 bases downstream of this with 100% homology to the consensus sequence. In contrast to previously identified p53 binding DNA sequences, the downstream half-site is inverted. We propose that the HGF/SF promoter can be activated by wild-type p53 in vivo and that this could be as a result of a novel form of sequence-specific DNA binding.

Full Text

The Full Text of this article is available as a PDF (71.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aravamudan B., Watabe M., Watabe K. Characterization of the 5'-flanking region of the hepatocyte growth factor gene. Biochem Biophys Res Commun. 1993 Aug 31;195(1):346–353. doi: 10.1006/bbrc.1993.2050. [DOI] [PubMed] [Google Scholar]
  2. Bottaro D. P., Rubin J. S., Faletto D. L., Chan A. M., Kmiecik T. E., Vande Woude G. F., Aaronson S. A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991 Feb 15;251(4995):802–804. doi: 10.1126/science.1846706. [DOI] [PubMed] [Google Scholar]
  3. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B. R., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995 Oct 19;377(6550):646–649. doi: 10.1038/377646a0. [DOI] [PubMed] [Google Scholar]
  4. Cooper K. p53 mutations in human papillomavirus-associated oesophageal squamous cell carcinoma. Br J Cancer. 1995 Nov;72(5):1337–1337. doi: 10.1038/bjc.1995.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cortner J., Vande Woude G. F., Rong S. The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. EXS. 1995;74:89–121. doi: 10.1007/978-3-0348-9070-0_6. [DOI] [PubMed] [Google Scholar]
  6. Deb S. P., Muñoz R. M., Brown D. R., Subler M. A., Deb S. Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene. 1994 May;9(5):1341–1349. [PubMed] [Google Scholar]
  7. Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A., Jr, Butel J. S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19;356(6366):215–221. doi: 10.1038/356215a0. [DOI] [PubMed] [Google Scholar]
  8. Eagles G., Warn A., Ball R. Y., Baillie-Johnson H., Arakaki N., Daikuhara Y., Warn R. M. Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Br J Cancer. 1996 Feb;73(3):377–381. doi: 10.1038/bjc.1996.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gohda E., Matsunaga T., Kataoka H., Takebe T., Yamamoto I. Induction of hepatocyte growth factor in human skin fibroblasts by epidermal growth factor, platelet-derived growth factor and fibroblast growth factor. Cytokine. 1994 Nov;6(6):633–640. doi: 10.1016/1043-4666(94)90051-5. [DOI] [PubMed] [Google Scholar]
  10. Gohda E., Nakamura S., Yamamoto I., Minowada J. Hepatocyte growth factor--pleiotropic cytokine produced by human leukemia cells. Leuk Lymphoma. 1995 Oct;19(3-4):197–205. doi: 10.3109/10428199509107889. [DOI] [PubMed] [Google Scholar]
  11. Gohda E., Nakamura S., Yamamoto I., Minowada J. Hepatocyte growth factor--pleiotropic cytokine produced by human leukemia cells. Leuk Lymphoma. 1995 Oct;19(3-4):197–205. doi: 10.3109/10428199509107889. [DOI] [PubMed] [Google Scholar]
  12. Gorman C. M., Moffat L. F., Howard B. H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982 Sep;2(9):1044–1051. doi: 10.1128/mcb.2.9.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gottlieb T. M., Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta. 1996 Jun 7;1287(2-3):77–102. doi: 10.1016/0304-419x(95)00019-c. [DOI] [PubMed] [Google Scholar]
  14. Graham F. L., van der Eb A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973 Apr;52(2):456–467. doi: 10.1016/0042-6822(73)90341-3. [DOI] [PubMed] [Google Scholar]
  15. Higashio K., Shima N., Goto M., Itagaki Y., Nagao M., Yasuda H., Morinaga T. Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. Biochem Biophys Res Commun. 1990 Jul 16;170(1):397–404. doi: 10.1016/0006-291x(90)91287-3. [DOI] [PubMed] [Google Scholar]
  16. Hino M., Inaba M., Goto H., Nishizawa Y., Tatsumi N., Nishino T., Morii H. Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. Br J Cancer. 1996 Jan;73(1):119–123. doi: 10.1038/bjc.1996.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  18. Kastan M. B., Zhan Q., el-Deiry W. S., Carrier F., Jacks T., Walsh W. V., Plunkett B. S., Vogelstein B., Fornace A. J., Jr A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992 Nov 13;71(4):587–597. doi: 10.1016/0092-8674(92)90593-2. [DOI] [PubMed] [Google Scholar]
  19. Matsumoto K., Nakamura T. Hepatocyte growth factor: molecular structure, roles in liver regeneration, and other biological functions. Crit Rev Oncog. 1992;3(1-2):27–54. [PubMed] [Google Scholar]
  20. Matsumoto K., Okazaki H., Nakamura T. Up-regulation of hepatocyte growth factor gene expression by interleukin-1 in human skin fibroblasts. Biochem Biophys Res Commun. 1992 Oct 15;188(1):235–243. doi: 10.1016/0006-291x(92)92375-8. [DOI] [PubMed] [Google Scholar]
  21. Matsumoto K., Tajima H., Hamanoue M., Kohno S., Kinoshita T., Nakamura T. Identification and characterization of "injurin," an inducer of expression of the gene for hepatocyte growth factor. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3800–3804. doi: 10.1073/pnas.89.9.3800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Matsumoto K., Tajima H., Okazaki H., Nakamura T. Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. J Biol Chem. 1992 Dec 15;267(35):24917–24920. [PubMed] [Google Scholar]
  23. Nakamura S., Gohda E., Matsuo Y., Yamamoto I., Minowada J. Significant amount of hepatocyte growth factor detected in blood and bone marrow plasma of leukaemia patients. Br J Haematol. 1994 Jul;87(3):640–642. doi: 10.1111/j.1365-2141.1994.tb08330.x. [DOI] [PubMed] [Google Scholar]
  24. Noji S., Tashiro K., Koyama E., Nohno T., Ohyama K., Taniguchi S., Nakamura T. Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situ hybridization. Biochem Biophys Res Commun. 1990 Nov 30;173(1):42–47. doi: 10.1016/s0006-291x(05)81018-6. [DOI] [PubMed] [Google Scholar]
  25. Okazaki H., Matsumoto K., Nakamura T. Partial purification and characterization of 'injurin-like' factor which stimulates production of hepatocyte growth factor. Biochim Biophys Acta. 1994 Feb 17;1220(3):291–298. doi: 10.1016/0167-4889(94)90151-1. [DOI] [PubMed] [Google Scholar]
  26. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol. 1994 Jun;5(3):221–227. [PubMed] [Google Scholar]
  27. Parenti A. R., Rugge M., Frizzera E., Ruol A., Noventa F., Ancona E., Ninfo V. p53 overexpression in the multistep process of esophageal carcinogenesis. Am J Surg Pathol. 1995 Dec;19(12):1418–1422. doi: 10.1097/00000478-199512000-00008. [DOI] [PubMed] [Google Scholar]
  28. Pavletich N. P., Chambers K. A., Pabo C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993 Dec;7(12B):2556–2564. doi: 10.1101/gad.7.12b.2556. [DOI] [PubMed] [Google Scholar]
  29. Plaschke-Schlütter A., Behrens J., Gherardi E., Birchmeier W. Characterization of the scatter factor/hepatocyte growth factor gene promoter. Positive and negative regulatory elements direct gene expression to mesenchymal cells. J Biol Chem. 1995 Jan 13;270(2):830–836. doi: 10.1074/jbc.270.2.830. [DOI] [PubMed] [Google Scholar]
  30. Rolley N., Butcher S., Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene. 1995 Aug 17;11(4):763–770. [PubMed] [Google Scholar]
  31. Rong S., Donehower L. A., Hansen M. F., Strong L., Tainsky M., Jeffers M., Resau J. H., Hudson E., Tsarfaty I., Vande Woude G. F. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res. 1995 May 1;55(9):1963–1970. [PubMed] [Google Scholar]
  32. Rubin J. S., Chan A. M., Bottaro D. P., Burgess W. H., Taylor W. G., Cech A. C., Hirschfield D. W., Wong J., Miki T., Finch P. W. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):415–419. doi: 10.1073/pnas.88.2.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995 Feb 23;373(6516):699–702. doi: 10.1038/373699a0. [DOI] [PubMed] [Google Scholar]
  34. Seki T., Hagiya M., Shimonishi M., Nakamura T., Shimizu S. Organization of the human hepatocyte growth factor-encoding gene. Gene. 1991 Jun 30;102(2):213–219. doi: 10.1016/0378-1119(91)90080-u. [DOI] [PubMed] [Google Scholar]
  35. Shin T. H., Paterson A. J., Kudlow J. E. p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53. Mol Cell Biol. 1995 Sep;15(9):4694–4701. doi: 10.1128/mcb.15.9.4694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stoker M., Gherardi E., Perryman M., Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987 May 21;327(6119):239–242. doi: 10.1038/327239a0. [DOI] [PubMed] [Google Scholar]
  37. Takada N., Yano Y., Matsuda T., Otani S., Osugi H., Higashino M., Kinoshita H., Fukushima S. Expression of immunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. Cancer Lett. 1995 Nov 6;97(2):145–148. doi: 10.1016/0304-3835(95)03967-2. [DOI] [PubMed] [Google Scholar]
  38. Takada N., Yano Y., Matsuda T., Otani S., Osugi H., Higashino M., Kinoshita H., Fukushima S. Expression of immunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. Cancer Lett. 1995 Nov 6;97(2):145–148. doi: 10.1016/0304-3835(95)03967-2. [DOI] [PubMed] [Google Scholar]
  39. Tanaka H., Shibagaki I., Shimada Y., Wagata T., Imamura M., Ishizaki K. Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Int J Cancer. 1996 Jan 26;65(3):372–376. doi: 10.1002/(SICI)1097-0215(19960126)65:3<372::AID-IJC16>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  40. Tuck A. B., Park M., Sterns E. E., Boag A., Elliott B. E. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol. 1996 Jan;148(1):225–232. [PMC free article] [PubMed] [Google Scholar]
  41. Vikhanskaya F., Erba E., D'Incalci M., Broggini M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res. 1994 Mar 25;22(6):1012–1017. doi: 10.1093/nar/22.6.1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell. 1992 Aug 21;70(4):523–526. doi: 10.1016/0092-8674(92)90421-8. [DOI] [PubMed] [Google Scholar]
  43. Weidner K. M., Behrens J., Vandekerckhove J., Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol. 1990 Nov;111(5 Pt 1):2097–2108. doi: 10.1083/jcb.111.5.2097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. el-Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992 Apr;1(1):45–49. doi: 10.1038/ng0492-45. [DOI] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES